AVI BIOPHARMA INC

Form 4 May 21, 2008

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB APPROVAL OMB

Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Last)

(Print or Type Responses)

1. Name and Address of Reporting Person *

FARA JOHN W PHD

(First)

(Middle)

2. Issuer Name and Ticker or Trading Symbol

AVI BIOPHARMA INC [AVII]

3. Date of Earliest Transaction

ONE SW COLUMBIA, SUITE 1105 05/20/2008

(Month/Day/Year)

4. If Amendment, Date Original

Filed(Month/Day/Year)

3.

X_ Director 10% Owner Officer (give title

__X__ Other (specify below)

below) Director

6. Individual or Joint/Group Filing(Check

5. Relationship of Reporting Person(s) to

(Check all applicable)

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

Issuer

PORTLAND, OR 97258

(City) (State) (Zip)

(Street)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)

2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, if

(Month/Day/Year)

TransactionAcquired (A) or Code Disposed of (D) (Instr. 3, 4 and 5) (Instr. 8)

Securities Beneficially Owned Following Reported

5. Amount of

6. Ownership 7. Nature of Form: Direct (D) or Indirect (I) (Instr. 4)

Indirect Beneficial Ownership (Instr. 4)

(9-02)

(A) or

Transaction(s) (Instr. 3 and 4) Price

500

Common Stock

Code V Amount (D)

4. Securities

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: AVI BIOPHARMA INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Ar Underlying Se (Instr. 3 and 4)
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title
Non-Qualified Stock Option (right to buy)	\$ 1.55	05/20/2008		A	20,000	06/20/2008(1)	05/20/2018	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 2.24					06/15/2005(1)	05/18/2015	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 2.55					06/05/2004(1)	05/05/2014	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 3.03					06/22/2007(1)	05/22/2017	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 4.64					06/24/2006(1)	05/24/2016	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 7.1875					08/02/2001(3)	08/02/2010	Common Stock

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
FARA JOHN W PHD ONE SW COLUMBIA, SUITE 1105 PORTLAND, OR 97258	X			Director		
Signatures						
By: Mark M Webber, Attorney-in-fact John Fara	For:	05/21/2008				
**Signature of Reporting Person		Date				

Reporting Owners 2

Edgar Filing: AVI BIOPHARMA INC - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Option Grant vests monthly until all shares are vested one year from date of grant.
- (2) Price not required on initial report of stock option granted.
- (3) Option Grant vests 25% per year on grant date with all shares vesting four years from date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.